个人简介：
研究员，博士生导师。美国俄克拉荷马大学病理学博士，加州大学圣地亚哥分校博士后。课题组主要研究方向为儿童恶性血液肿瘤的发病机制和精准治疗，针对儿童白血病研发多个具有转化潜力的配体蛋白偶联药物。以第一或通讯作者在Blood、Cell Reports Medicine、Journal of Advanced Research、Journal of Hematology and Oncology等高水平期刊发表论文20余篇，包括ESI高被引/热点论文1篇，总引用超1500次。研究团队于2020-2023连续四年在美国血液学年会上取得杰出摘要奖，2025两项会议口头汇报。主持科研项目包括国自然面上/青年基金、广东省基础与应用基础研究基金、深圳市科创委面上项目等10项。
个人履历：
(1) 2025-01 至 今, 中山大学, 附属第七医院, 研究员
(2) 2018-03 2024-12, 中山大学, 附属第七医院, 副研究员
(3) 2015-08 至 2018-02, 加州大学圣地亚哥分校 ,合作导师：Dr. Thomas J Kipps
(4) 2010-08 至 2015-07, 俄克拉荷马大学, 病理学, 博士 ,导师：Dr. Zhizhuang Joe Zhao
(5) 2004-09 至 2008-08, 吉林大学, 生命科学学院, 生物技术, 学士
课题方向：罕见儿童血液肿瘤
发表论文：
1. Dengyang Zhang, Yao Guo, Zhiyong Peng, Yan Xiao, Zhiguang Chang, Liuting Yu, Yuming Zhao, Qi Zhang, Lingling Ma, Shuping Li, Chi-Kong Li, Kam Tong Leung, Zhizhuang Joe Zhao, Chun Chen1, Yun Chen; FLT3L-Based Drug Conjugate Effectively Targets Chemoresistant Leukemia Stem Cells in Acute Myeloid Leukemia, Cell Reports Medicine, 2025 Sep 19:102365.
2. Na Li; Stefanie Steiger; Yao Guo; Muzheng Li; Zheqi Wen; Mingcheng Huang; Chuyu Xie; Shan Jiang; Dengyang Zhang; Yuming Zhao; Liuting Yu; Xiaohua Wang; Zhihua Zheng; Zhizhuang Joe Zhao; Yun Chen; Tubular epithelial cell-derived Flt3L is required for type 1 conventional dendritic cell (cDC1) activation and expansion in promoting the recovery in acute kidney injury, Journal of Advanced Research, 2025 Feb 27:S2090-1232(25)00134-1. PMID: 40023248.
3. Pei, Han Zhong; Guo, Yao; Zhao, Yuming; Zhang, Dengyang; Chang, Zhiguang; Zhou, Jingfeng; Baek, Suk-Hwan; Zhao, Zhizhuang Joe; Chen, Chun; Chen, Yun; FLT3 inhibitors induce p53 instability, driven by STAT5/MDM2/p53 competitive interactions in acute myeloid leukemia, Cancer Letters, 2025 Jan 3:611:217446. PMID: 39756787.
4. Yong Liu, Zefan Du, Lindi Li, Junbin Huang, Su Liu, Bo Lu, Yifei Duan, Yucai Cheng, Tianwen Li, Jing Zhang, Jiani Mo, Yalin Yang, Wengqing Wang, Hailin Zou, Tianqi Liang, Meng Jiang, Mo Yang#, Yun Chen#, Cheng Ouyang#, Chun Chen#. scRNA-seq reveals an immune microenvironment and JUN-mediated NK cell exhaustion in relapsed T-ALL. Cell Reports Medicine. 2025;6(5):102098.
5. Dengyang Zhang, Chunxiao He, Yao Guo, Jianfeng Li, Bo Li, Yuming Zhao, Liuting Yu, Zhiguang Chang, Hanzhong Pei, Ming Yang, Na Li, Qi Zhang, Yulong He, Yihang Pan, Zhizhuang Joe Zhao, Changhua Zhang, Yun Chen; Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor, BMC Medicine, 2022, 20:257. PMID: 35999600.
6. Yuming Zhao, Chunxiao He, Dengyang Zhang, Yao Guo, Zhiyong Peng, Liuting Yu, Na Li, Chun Chen, Zhizhuang Joe Zhao, Yun Chen; Leukemogenic SHP2 mutations lead to erythropoietin independency of HCD-57 cells: a novel model for preclinical research of SHP2-mutant JMML, Exp Hematol Oncol, 2023, 12:20. PMID: 36805832.
7. Chunxiao He, Zhiyong Peng, Dengyang Zhang, Yao Guo, Tianqi Liang, Yuming Zhao, Liuting Yu, Qi Zhang, Zhiguang Chang, Yan Xiao, Na Li, Hongman Xue, Shunjie Wu, Zhizhuang Joe Zhao, Changhua Zhang, Yun Chen; Sunitinib selectively targets leukemogenic signaling of mutant SHP2 in juvenile myelomonocytic leukemia. Biochem Pharmacol, 2023, 213:115588. PMID: 37187274.
8. Han Zhong Pei, Zhiyong Peng, Xiaomei Zhuang, Xiaobo Wang, Bo Lu, Yao Guo, Yuming Zhao, Dengyang Zhang, Yunjun Xiao, Tianshun Gao, Liuting Yu, Chunxiao He, Shunjie Wu, Suk-Hwan Baek, Zhizhuang Joe Zhao, Xiaojun Xu, Yun Chen; miR-221/222 induce instability of p53 By downregulating deubiquitinase YOD1 in acute myeloid leukemia, Cell Death Discovery, 2023, 9:249. PMID: 37454155.
9. Yao Guo, Hanzhong Pei, Bo Lu, Dengyang Zhang, Yuming Zhao, Fuqun Wu, Honghua Sun, Junbin Huang, Peng Li, Chenju Yi, Chengming Zhu, Yihang Pan, Shunjie Wu, Chun Chen, Xiaojun Xu, Yun Chen; Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia. Cell Death Discovery, 2022;8:82. PMID: 35210425.
10. Zhang, Dengyang; Guo, Yao; Zhao, Yuming; Yu, Liuting; Chang, Zhiguang; Pei, Hanzhong; Huang, Junbin; Chen, Chun; Xue, Hongman; Xu, Xiaojun; Pan, Yihang; Li, Ningning; Zhu, Chengming; Zhao, Zhizhuang Joe; Yu, Jian; Chen, Yun; Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression, Microbial Cell Factories, 2021, 20(1):67. PMID: 33691697.
11. Chen, Yun; Guo, Yao; Pan, Yihang; Zhao, Zhizhuang Joe; Structure analysis of the receptor binding of 2019-nCoV, Biochemical and Biophysical Research Communications, 2020, 525(1): 135-140. PMID: 32081428 IF 2.2
12. Chen, Yun; Guo, Yao; Han, Jiayu; Ho, Wanting Tina; Li, Shibo; Fu, Xueqi; Zhao, Zhizhuang Joe. Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity. Journal of Hematology & Oncology. 2012;5:39.
13. Guo, Yao; Chen, Yun; Xu, Xuesong; Fu, Xueqi; Zhao, Zhizhuang Joe. SU11652 inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. Journal of Hematology & Oncology. 2012;5:72.
14. Chen, Yun; Guo, Yao; Zhao, Wanke; Ho, Wanting Tina; Fu, Xueqi; Zhao, Zhizhuang Joe. Identification of an orally available compound with potent and broad FLT3 inhibition activity. Oncogene. 2016;35(23):2971–2978.
15. Chen, Yun; Chen, Liguang; Yu, Jian; Ghia, Emanuela M; Choi, Michael Y; Zhang, Ling; Zhang, Suping; Sanchez Lopez, Elsa; Widhopf, George F , II; Messer, Karen; Rassenti, Laura Z; Jamieson, Catriona; Kipps, Thomas J. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019;134(13):1084–1094.
16. Guo, Yao; Sun, Honghua; Zhang, Dengyang; Zhao, Yuming; Shi, Mingxia; Yang, Ming; Xing, Shu; Fu, Xueqi; Bin, Ting; Lu, Bo; Wu, Shunjie; Xu, Xiaojun; Xu, Xuesong; Chen, Yun#; Zhizhuang Joe Zhao#. Development of a highly sensitive method for detection of FLT3D835Y. Biomarker Research. 2020;8:30.